Appendix B: Provincial Case Definitions for Reportable Diseases

Disease: Pneumococcal disease, invasive

Revised December 2014
Pneumococcal disease, invasive

1.0 Provincial Reporting
   Confirmed cases of disease

2.0 Type of Surveillance
   Case-by-case

3.0 Case Classification

3.1 Confirmed Case
   Clinical evidence of invasive disease (see section 5.0) with laboratory confirmation of infection:
   - Isolation of *Streptococcus pneumoniae* from a normally sterile site (e.g., blood, cerebrospinal fluid [CSF]), excluding the middle ear
     OR
   - Detection of *S. pneumoniae* deoxyribonucleic acid (DNA) by nucleic acid amplification test (NAAT) from a normally sterile site (e.g., blood, CSF), excluding the middle ear

3.2 Probable Case
   Clinical evidence of invasive disease and no other apparent cause with non-confirmatory laboratory evidence:
   - Demonstration of *S. pneumoniae* antigen from a normally sterile site (e.g., blood CSF), excluding the middle ear

   Note: Probable case definitions are provided as guidelines to assist with case finding and health management, and are not for provincial notification purposes.

4.0 Laboratory Evidence

4.1 Laboratory Confirmation
   Any of the following will constitute a confirmed case of invasive pneumococcal disease:
   - Positive *S. pneumoniae* culture from a normally sterile site excluding the middle ear
   - Positive NAAT for *S. pneumoniae* from a normally sterile site excluding the middle ear

4.2 Approved/Validated Tests
   - Standard culture for *S. pneumoniae*
   - NAAT for *S. pneumonia* (includes polymerase chain reaction (PCR))
   - *S. pneumoniae* antigen test
   - Consult with laboratory about appropriate tests and specimens
Note: Isolates should be sent to the Public Health Ontario Laboratories (PHOL) for serotype determination and further characterization. Isolates are also submitted by the PHOL to the National Microbiology Laboratory (NML) for national surveillance.

4.3 Indications and Limitations

- Sputum and bronchial lavages are not considered sterile specimens
- Detection of *S. pneumoniae* antigen does not allow case confirmation or determination of serotype
- Detection from sterile site specimens by NAAT can be attempted by PHOL when cultures at the initial testing laboratory are negative and IPD is suspected – contact PHOL prior to submitting sample to obtain PHO Medical/Clinical Microbiologist approval

Note: CSF is the only sterile site current commercial kits are verified for use on

5.0 Clinical Evidence

Clinical illness associated with invasive disease manifests itself mainly as pneumonia with bacteremia, bacteremia without a known site of infection, and meningitis. Pneumonia without bacteremia is not reportable.

6.0 ICD Code(s)

6.1 ICD-10 Code(s)

A40.3 Septicaemia due to *S. pneumoniae*

B95.3 *S. pneumoniae* as the cause of diseases classified elsewhere, e.g.:

- I30.1 Infective pericarditis
- K65.0 Acute peritonitis
- M00.8 Arthritis and polyarthritis due to other specified bacterial agents
- O85 Puerperal sepsis
- P23.6 Congenital pneumonia due to other bacterial agents

G00.1 Meningitis due to *S. pneumoniae*

J13 Pneumonia due to *S. pneumoniae*

M00.1 Pneumococcal arthritis and polyarthritis

6.2 ICD-9/ICD-9CM Code(s)

038.2 Septicaemia due to *S. pneumoniae*

041.2 *S. pneumoniae* of unspecified site and as the cause of diseases classified elsewhere, e.g.:

- 420.9 Infective pericarditis
- 711.0 Pyogenic arthritis
- 567.1 Pneumococcal peritonitis

320.1 Meningitis due to *S. pneumoniae*
Pneumonia due to *S. pneumoniae*

711.0 Pneumococcal arthritis and polyarthritis

7.0 Comments

Determination of serotype from a sterile site isolate and further characterization by a reference laboratory are important in monitoring changes in disease epidemiology, including the impact of vaccination programs, potential serotype replacement, and antibiotic resistance.

8.0 Sources


9.0 Document History

Table 1: History of Revisions

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Document Section</th>
<th>Description of Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2014</td>
<td>General</td>
<td>New template.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acronym for nucleic acid amplification test changed from “NAT” to “NAAT”.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Title of Section 8.0 changed from “References” to “Sources”.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 9.0 Document History added.</td>
</tr>
<tr>
<td>December 2014</td>
<td>3.1 Confirmed Case</td>
<td>End of sentence removed: “…(organism detected) with invasive disease (See Section 5.0)”.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>New addition to beginning of sentence: “Clinical evidence of invasive disease (see Section 5.0) with…”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DNA spelled out: “deoxyribonucleic acid”.</td>
</tr>
<tr>
<td>December 2014</td>
<td>3.2 Probable Case</td>
<td>First paragraph revised.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At beginning of bullet, “Detection…” removed and “Demonstration…” added.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Note added: “Note: Probable case definitions are provided as guidelines to assist with case finding and health management, and are not for provincial notification purposes.”</td>
</tr>
<tr>
<td>Revision Date</td>
<td>Document Section</td>
<td>Description of Revisions</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| December 2014 | 4.2 Approved/Validated Tests   | Ending of second bullet added: “…(includes polymerase chain reaction (PCR))”. Fourth bullet added: “Consult with laboratory about appropriate tests and specimens”. Note added: “Note: Isolates should be sent to the Public Health Ontario Laboratories (PHOL) for serotype determination and further characterization. Isolates are also submitted by the PHOL to the National Microbiology Laboratory (NML) for national surveillance”.
| December 2014 | 4.3 Indications and Limitations | Entire section revised.                                                                                                                                                                                                      |
| December 2014 | 5.0 Clinical Evidence          | New addition to beginning of sentence: “Clinical illness associated with…” Removal of “… infection, or meningitis” replaced with “…infection and meningitis”.                                                                 |
| December 2014 | 7.0 Comments                   | Bullet removed: “Isolates should be sent to the Public Health Laboratories of the OAHPP for serotyping or further characterization”.                                                                                      |
| December 2014 | 8.0 Sources                    | Updated.                                                                                                                                                                                                                  |